Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM) from its SEC filings: 2025 revenue $521.3 million (+55% vs the year before), net margin -4%, free cash flow $54.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $521.3 million |
| Revenue growth | +55% |
| Net income | -$23.4 million |
| Net margin | -4.5% |
| Free cash flow | $54.9 million |
| Diluted EPS | $-0.47 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +38% |
| Cash | $330.7 million |
| Share count, 1 year | +29% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.